Guardant Health (NASDAQ:GH) had its price target lifted by JPMorgan Chase & Co. from $42.00 to $85.00 in a research note issued to investors on Wednesday, The Fly reports. The firm currently has an overweight rating on the stock.
Separately, Bank of America reissued a neutral rating and set a $60.00 price objective (up previously from $42.00) on shares of Guardant Health in a research note on Thursday, February 28th. One investment analyst has rated the stock with a hold rating and four have given a buy rating to the stock. The stock presently has an average rating of Buy and a consensus price target of $72.50.
Shares of NASDAQ GH opened at $97.98 on Wednesday. Guardant Health has a 12-month low of $27.04 and a 12-month high of $106.58. The stock has a market capitalization of $8.48 billion and a price-to-earnings ratio of -34.99.
In other news, major shareholder Vision Fund (Aiv M1) Softbank acquired 2,033,990 shares of Guardant Health stock in a transaction that occurred on Tuesday, March 12th. The shares were acquired at an average price of $9.83 per share, with a total value of $19,994,121.70. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.
Several institutional investors and hedge funds have recently made changes to their positions in GH. Benjamin F. Edwards & Company Inc. purchased a new position in Guardant Health during the fourth quarter worth approximately $26,000. Financial Advocates Investment Management purchased a new position in Guardant Health during the fourth quarter worth approximately $220,000. Legal & General Group Plc purchased a new position in Guardant Health during the fourth quarter worth approximately $85,000. Citigroup Inc. purchased a new position in Guardant Health during the fourth quarter worth approximately $94,000. Finally, Victory Capital Management Inc. purchased a new position in Guardant Health during the fourth quarter worth approximately $124,000. 69.54% of the stock is currently owned by institutional investors and hedge funds.
Guardant Health Company Profile
Guardant Health, Inc, a precision oncology company, provides non-invasive cancer diagnostics. It offers liquid biopsy tests for advanced stage cancer, such as Guardant360, a molecular diagnostic test that measures various cancer-related genes from circulating tumor DNA (ctDNA); and GuardantOMNI, a broader panel measuring various genes from ctDNA.
Recommended Story: What is a Futures Contract?
Receive News & Ratings for Guardant Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Guardant Health and related companies with MarketBeat.com's FREE daily email newsletter.